Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | MGMT | P16455 | 3/20 | 0.37 |
| ▸ | BRAF | P15056 | 6/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16146754 | 0.83 | GDA (0.39) | GDABRAFGAAL3MBTL1ALDH1A1 | |
| SCHEMBL16146678 | 0.83 | GDA (0.39) | GDABRAFGAAL3MBTL1ALDH1A1 | |
| SCHEMBL16146526 | 0.83 | ADORA3 (0.43) | GDABRAFGAAL3MBTL1ALDH1A1 | |
| SCHEMBL9021288 | 0.83 | CYP1A2 (0.40) | GDABRAFL3MBTL1ALDH1A1 | |
| SCHEMBL16146213 | 0.81 | GDA (0.38) | GDABRAFGAAL3MBTL1ALDH1A1 | |
| SCHEMBL14196063 | 0.81 | XDH (0.40) | GDABRAFL3MBTL1 | |
| SCHEMBL16145714 | 0.81 | GDA (0.38) | GDABRAFGAAL3MBTL1ALDH1A1 | |
| SCHEMBL16146723 | 0.81 | GDA (0.38) | GDABRAFGAAL3MBTL1ALDH1A1 | |
| SCHEMBL19738339 | 0.80 | SYK (0.39) | L3MBTL1 | |
| SCHEMBL16145842 | 0.79 | GDA (0.40) | GDABRAFGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-115052986-A | Compositions comprising nucleases and uses thereof | 阿伯生物技术公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-113661242-A | Compositions comprising modified cyclic polyribonucleotides and uses thereof | 旗舰创业创新第六有限责任公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113543770-A | Compositions, methods and kits for delivery of polyribonucleotides | 旗舰创业创新第六有限责任公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113543766-A | Polyribonucleotides and their cosmetic use | 旗舰创业创新第六有限责任公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-113453707-A | RNA for malaria vaccine | 库瑞瓦格股份公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-111819185-A | Compositions comprising cyclic polyribonucleotides and uses thereof | 旗舰创业创新第六有限责任公司 | 2020-10-23 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| EP-1525209-B1 | 1'-, 2'- AND 3' -MODIFIED NUCLEOSIDE DERIVATIVES FOR TREATING FLAVIVIRIDAE INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-7662798-B2 | 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections | IDENIX PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | GDA 1170/4885MGMT 3321/4885BRAF 1974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.